News & Updates
Filter by Specialty:
DAPT with cilostazol reduces stroke recurrence without raising bleeding risk
Dual antiplatelet therapy (DAPT) using cilostazol appears to be more beneficial than single antiplatelet therapy, with the results of a study suggesting that DAPT helps lower the incidence of ischemic stroke recurrence without increasing the risk of severe or life-threatening bleeding.
DAPT with cilostazol reduces stroke recurrence without raising bleeding risk
07 Feb 2023
Elevated blood pressure ups retinal vascular occlusion risk
Individuals with high blood pressure (BP), stage 1 hypertension, and stage 2 hypertension are at greater risk of retinal vascular occlusion relative to those with normal BP, as reported in a study.
Elevated blood pressure ups retinal vascular occlusion risk
05 Feb 2023
Add-on bevacizumab ups hypertension risk in CRC patients
The addition of bevacizumab (BVZ) to the standard regimen for the treatment of advanced colorectal cancer (CRC) appears to increase the risk of cardiovascular events, suggest the results of a meta-analysis presented at the recent ASCO Gastrointestinal Cancers Symposium (ASCO GI 2023).
Add-on bevacizumab ups hypertension risk in CRC patients
03 Feb 2023
Saroglitazar may lower cardiovascular risk in NAFLD
Treatment with the dual PPAR α/γ agonist saroglitazar helps improve the serum atherogenic lipoprotein profile in patients with nonalcoholic fatty liver disease (NAFLD), regardless of comorbid conditions and statin use, as shown in a study.
Saroglitazar may lower cardiovascular risk in NAFLD
03 Feb 2023
Prediabetes in youngsters linked to a nearly 80 percent increased risk of CVD
Prediabetes in youngsters is associated with an 88 percent lifetime risk of diabetes and a nearly 80 percent higher risk of cardiovascular disease (CVD), researchers from the Chinese University of Hong Kong (CUHK) have reported.
